Diagnostic Value of the Liver Inflammation Index for MASH in Patients With T2DM and MAFLD

Recruiting Observational Study
Type 2 Diabetes Mellitus (T2DM) MASH - Metabolic Dysfunction-Associated Steatohepatitis Metabolic Dysfunction-associated Fatty Liver Disease
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
10,000 (estimated)
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

This observational study aims to evaluate a new diagnostic tool, the Liver Inflammation Index, in detecting Metabolic Dysfunction-Associated Steatohepatitis (MASH) among adults who have both Type 2 Diabetes Mellitus (T2DM) and Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD).

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Adults aged ≥18 years, with no restrictions on sex; 2. Patients clinically diagnosed with metabolic dysfunction-associated fatty liver disease (MAFLD) according to the Chinese Society of Hepatology guideline Guidelines for the Prevention and Treatment of Metabolic Dysfunction…
Contacts

Yan Bi, MD,PhD

86-25-83-105302

biyan@nju.edu

CONTACT

Jin Li, MD,PhD

86-25-83-105302

jinli807@126.com

CONTACT